Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Print Friendly, PDF & Email

RE: FRIEDRICH’s ATAXIA- Preliminary data suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg – Company remains on track to report topline data from placebo – controlled single and multiple ascending dose clinical trials in Q2 2021 BALA CYNWYD, Pa., Dec. 08, 2020 (GLOBE […]